Preventing restenosis after PTCA - horizon scanning review

Record ID 32002000855
Authors' objectives:

To summarise the current research evidence on new technologies for restenosis.

Authors' recommendations: - Clinical impact: On an individual level vascular brachytherapy produces a significant reduction in the incidence of recurrent restenosis and therefore in the need for repeat revascularisation. However, to reach its full potential it will need to diffuse to more centres. It is difficult at this stage to estimate the clinical impact of drug eluting stents but they may be used for primary prevention ie at the first PTCA. - Service impact: The widespread diffusion of vascular brachytherapy will require adherence to licensing regulations for individuals and hospitals, and partnerships between interventional cardiologists, radiation physicists and medical oncologists. It is therefore difficult to foresee very rapid or widespread diffusion at this time. Drug eluting stents will have no additional service impact over and above current stent usage. - Patient issues: The introduction of these techniques is unlikely to raise any specific concerns for patients, and any reduction in the risk of restenosis and a reappearance of symptoms should be welcomed. - Financial and overall NHS impact: At this time it is difficult to estimate the financial impact of the introduction of these techniques although the use of drug eluting stents is likely to increase the cost of standard PTCA. Cost-effectiveness data is available for brachytherapy but not yet for drug eluting stents.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
URL for published report:
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Brachytherapy
  • Coronary Restenosis
  • Costs and Cost Analysis
  • Stents
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.